Risks of Lacosamide in Pregnancy
Lacosamide (Vimpat) crosses the placenta and may harm fetal development. Animal studies show embryo-fetal toxicity, including increased malformations and reduced offspring viability at doses similar to human levels. Human data is limited, with no controlled trials, but postmarketing reports and registries note risks like major congenital malformations (3-5% rate, higher than general population's 2-3%) and low birth weight.[1][2]
Is It Safe? Pregnancy Category and Recommendations
Lacosamide is FDA Pregnancy Category C—risk cannot be ruled out. The American Academy of Neurology advises against starting it in pregnancy due to insufficient safety data. Use only if benefits outweigh risks, typically for women already on it for uncontrolled seizures where alternatives fail. Neural tube defects are not strongly linked, unlike valproate, but overall malformation risk remains elevated.[1][3]
Monitoring and Testing During Use
- Enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry (call 1-888-233-2334) for ongoing data collection.
- Get baseline folic acid supplementation (at least 0.4 mg daily, often higher 4 mg for antiepileptic users) to reduce neural tube defects.
- Schedule early ultrasounds (e.g., 11-14 weeks) for anomaly screening, plus detailed fetal echocardiography and MRI if needed.
- Monitor maternal serum levels; dose adjustments may be required as pregnancy alters clearance (often increases in third trimester).[1][2][4]
Breastfeeding Considerations
Lacosamide passes into breast milk at low levels (about 15% of maternal dose). Monitor infant for sedation, poor feeding, or irritability. Weigh benefits of breastfeeding against formula; most experts say it's generally compatible with monitoring.[1][3]
Fertility, Planning, and Delivery Precautions
- Discuss contraception; lacosamide has no known impact on fertility but seizures do.
- Plan pregnancy with neurologist: taper or switch if possible pre-conception.
- During labor, watch for seizure breakthrough from sleep deprivation or stress; IV loading may be needed.
- Newborns face transient withdrawal risks—observe in NICU if high doses used.[2][4]
Alternatives and When to Switch
For epilepsy, consider lamotrigine or levetiracetam, which have better pregnancy safety profiles (lower malformation rates ~2-3%). Avoid polytherapy if possible, as it doubles risks. Consult a maternal-fetal medicine specialist for personalized switches.[3][4]
Sources
[1]: Lacosamide Prescribing Information (FDA)
[2]: NAAED Pregnancy Registry Interim Report
[3]: AAN/AEO Guidelines on Antiepileptic Drugs in Pregnancy
[4]: UpToDate: Antiseizure Medication Use in Pregnancy